Kodiak Sciences Inc.
NASDAQ:KODBiotechnology
-$0.03 today
- Market cap
- $6.40B
- Beta
- 2.21
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$3.73
Volume 0.74M
Average 1.10M
KOD Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Kodiak Sciences Inc.NASDAQ: KOD
Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Financing cash flow grows, but more slowly than its trailing trend
Q3 FY2026 financing cash flow of $6.38M rose 684.9% year over year, behind the +12713.7% change in trailing-twelve-month financing cash flow. Sequentially, it rose 115.4% from the prior quarter. Over 3 fiscal years it compounded at +354.8% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +684.9% toward the trailing-twelve-month pace of +12713.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 178.3M USD
- Year-over-year change
- +35489.2%
- 4-year CAGR
- +116.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 178.3M | +35489.2% |
| FY2024 | 2024-12-31 | 501K | +1516.1% |
| FY2023 | 2023-12-31 | 31K | -98.4% |
| FY2022 | 2022-12-31 | 1.9M | -76.8% |
| FY2021 | 2021-12-31 | 8.18M | — |
Financing Cash Flow vs competitors
How KOD compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +12713.7% is the highest of 9, against a peer median of +11.0%.
- Over three fiscal years its annual growth of +354.8% compares with a peer median of +108.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $4.65B USD | +16.5% | +54.4% | 29.9% | |
| LTM Mar 2026 | $557.83M USD | +3601.6% | +628.3% | 1072.0% | |
| LTM Sep 2026 | $187.21M USD | +12713.7% | +354.8% | — | |
| LTM Mar 2026 | $171.98M USD | +5.5% | — | 2258.5% | |
| LTM Mar 2026 | $124.44M USD | +575.7% | +232.1% | 141.0% | |
| LTM Jun 2026 | $116.25M USD | -52.9% | +40.6% | 2.2% | |
| LTM Mar 2026 | CHF 105.86M CHF | -32.9% | +370.6% | 21003.4% | |
| LTM Mar 2026 | $53.56M USD | -16.0% | -33.7% | 1199.5% | |
| LTM Mar 2026 | $47.24M USD | +93.8% | -8.9% | 14179.4% | |
BLTEBelite Bio, Inc | LTM Jun 2026 | $510.12K USD | — | +161.8% | — |
| Peer median (excluding KOD) | — | +11.0% | +108.1% | 1135.7% | |
Competitors are the stored peer set for KOD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (266.99M) | (333.82M) | (260.49M) | (176.21M) | (229.97M) |
| Depreciation & Amortization | 8.71M | 11M | 25.95M | 26.71M | 26.32M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 61.39M | 106.03M | 88.56M | 60.21M | 58.86M |
| Change in Working Capital | 14.43M | 11.96M | (7.36M) | (28.39M) | 6.85M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.09M) | 1.66M | 5.6M | (9.69M) | 8.07M |
| Other Working Capital | 16.52M | 10.3M | (12.95M) | (18.69M) | (1.22M) |
| Other Non-Cash Items | 198K | (1.63M) | (840K) | 355K | 1.93M |
| Operating Cash Flow | (182.27M) | (206.46M) | (154.18M) | (117.32M) | (136.01M) |
| Capital Expenditures | (63.3M) | (47.36M) | (41.43M) | (400K) | (506K) |
| Acquisitions (Net) | 0 | 0 | (290.65K) | 0 | 0 |
| Purchases of Investments | 0 | (427.77M) | (49.35M) | (355K) | 0 |
| Sales of Investments | 24.5M | 138M | 340M | 0 | 0 |
| Other Investing Activities | 0 | 616K | 290.65K | 0 | 0 |
| Investing Cash Flow | (38.8M) | (336.51M) | 249.23M | (755K) | (506K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 8.23M | 1.94M | 242K | 501K | 178.3M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (45K) | (49K) | (211K) | 0 | 0 |
| Financing Cash Flow | 8.18M | 1.9M | 31K | 501K | 178.3M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (212.89M) | (541.08M) | 95.07M | (117.57M) | 41.79M |
| Free Cash Flow | (245.57M) | (253.82M) | (195.61M) | (117.72M) | (136.51M) |
Kodiak Sciences Inc.
NASDAQ:KOD
Intrinsic Alpha fair value
Locked
Current Price
$97.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.